EpiBiologics launched in 2023 with a $50 million series A, having been founded to take forward the work of renowned antibody ...
Johnson & Johnson today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor ...
Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...
WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in NarcolepsyOn Track to Extend the Pitolisant Franchise ...
Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.
Major differences between eGFR based on cystatin C compared with creatinine were associated with higher rates for all-cause mortality, CV events and kidney failure for outpatients, according to data ...
Rybrevant Faspro, a subcutaneous therapy, offers a faster, less invasive treatment for EGFR-mutated NSCLC, reducing administration time and reactions compared to intravenous methods. The PALOMA-3 ...
Researchers have discovered novel biomarkers that could allow doctors to detect endometriosis in its earliest stages through ...
Google appears to have removed its AI-generated summaries for certain liver-related health searches after concerns were raised about the accuracy of the responses, TechCrunch reported Jan. 11. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback